AAM Sees ‘Red Flag’ In IQVIA Biosimilars Report
US Association’s Biosimilars Council Cautions Over Long-Term Market Sustainability
While the latest IQVIA data points to accelerated uptake of US biosimilars over the next five years, with associated increases in spending and savings, local off-patent industry association the AAM says the report raises a “red flag” over long-term market sustainability.
You may also be interested in...
Five years on from the first US biosimilar approval, the country’s biosimilars market is starting to fulfil its potential, in part driven by a recent oncology “revolution” according to Sandoz’ Sheila Frame.
A wave of recent biosimilar launches in the US has provided multi-source competition on several major brands and stands to boost the country’s biosimilars market, according to Sean McGowan, senior director of biosimilars at AmerisourceBergen.
Quarterly global Basaglar sales rose above $300m for the first time in the fourth quarter of 2019, with full-year turnover pushing the insulin glargine hybrid well into blockbuster territory.